Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

It has been revealed that CD109 expression is associated with prognosis in cancer patients, but it remains unclear thus far. Therefore, we performed a meta-analysis in the present study for a better assessment of the prognostic role of CD109 expression in cancer patients.

Methods

Eligible studies were collected through a search of the PubMed, Embase, Cochrane Library, and Scopus databases. The pooled hazard ratio (HR) with 95% confidence interval (CI) was evaluated to reveal the association between CD109 expression and overall survival (OS) in cancer patients.

Results

Seven studies with 1583 patients were enrolled. The pooled HR with 95% CI was calculated as 2.31 (95% CI 1.93-2.76, P < .001), suggesting an association between high expression of CD109 and un

SUBMITTER: Koh HM 

PROVIDER: S-EPMC7982172 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature